Muscle Protein Metabolism in Obesity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2020-02-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obesity is associated with reduced adenosine triphosphate (ATP) turnover in skeletal muscle, a condition that can impair muscle metabolism. The proposed research will discover mechanisms responsible for decreased content in mitochondrial proteins as well as in protein β-F1-ATPase, which is directly responsible for ATP assembly, in the muscle of obese individuals. This research will further examine the effectiveness of interventions, such as increased plasma amino acid availability and exercise, to increase the rate of production of mitochondrial proteins as well as that of β-F1-ATPase in the muscle of obese individuals. The findings will help to develop appropriate interventions to improve muscle ATP turnover and metabolism in obese people.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Calorie Restriction on Accumulation of Old, Modified Proteins in Abdominally Obese Adults

NCT01497106

Insulin Resistance

COMPLETED NA

Resistance Exercise and Muscle Protein Synthesis in Obese Adults

NCT03411681

Obesity

COMPLETED NA

Muscle Protein Synthesis Rates After Protein Consumption in Lean, Overweight, and Obese Adults

NCT02613767

Obesity

COMPLETED

Exercise and Nutrition Interventions in Age-related Sarcopenia

NCT02912130

Sarcopenia Muscular Atrophy

COMPLETED NA

Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology

NCT03012139

Metastatic Cancer Cachexia; Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amino Acid Infusion in Lean

Group Type EXPERIMENTAL

Increase in the levels of plasma amino acids

Intervention Type OTHER

Aminosyn 15%; 160 mg/kg FFM/h for 4 hours

Amino acid Infusion in Obese

Group Type EXPERIMENTAL

Increase in the levels of plasma amino acids

Intervention Type OTHER

Aminosyn 15%; 160 mg/kg FFM/h for 4 hours

Exercise in lean

Group Type EXPERIMENTAL

Aerobic exercise

Intervention Type OTHER

Moderate intensity for 45 minutes

Exercise in Obese

Group Type EXPERIMENTAL

Aerobic exercise

Intervention Type OTHER

Moderate intensity for 45 minutes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Increase in the levels of plasma amino acids

Aminosyn 15%; 160 mg/kg FFM/h for 4 hours

Intervention Type OTHER

Aerobic exercise

Moderate intensity for 45 minutes

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Body mass index (BMI): lean, 19-26 kg/m2; obese, 30-40 kg/m2
2. Availability of transportation
3. Ability to sign informed consent form

Exclusion Criteria

1. Medication or supplements (i.e. amino acids, protein) known to affect protein metabolism
2. Presence of acute illness
3. History of liver disease
4. Uncontrolled metabolic disease
5. ECG documented abnormalities, atrial fibrillation, history of syncope, limiting or unstable angina, or congestive heart failure
6. Chronically elevated blood pressure (systolic, \>140 mmHg; diastolic, \>100 mmHg)
7. Cardiac pacemaker or other medical device implanted in the body
8. Low hemoglobin or hematocrit
9. Current participation in a weight-loss regimen, including extreme dietary practices
10. Smoking
11. Use of anabolic steroids or corticosteroids (within 3 months)

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes